Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
Alnylam Pharmaceuticals expects its Japan sales to roughly double within the next few years, fueled by the label expansion of Amvuttra (vutrisiran) into transthyretin amyloid cardiomyopathy (ATTR-CM) earlier this year. “We believe we can double our business in Japan,” Alnylam…
To read the full story
Related Article
- Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
July 18, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- Alnylam’s Amvuttra Hits Japan Market for hATTR Amyloidosis
November 21, 2022
- Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
BUSINESS
- Astellas Cuts Costs Ahead of Schedule, Key Assets Entering Late Stages
February 5, 2026
- Astellas Lifts Full-Year Forecast, Drops 2 Pipeline Programs
February 5, 2026
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- MSA Drug NPC-29 Set to Enter PIII This Month: Nobelpharma CEO
February 5, 2026
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…